RU2386633C2 - 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения - Google Patents
1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения Download PDFInfo
- Publication number
- RU2386633C2 RU2386633C2 RU2006143153/04A RU2006143153A RU2386633C2 RU 2386633 C2 RU2386633 C2 RU 2386633C2 RU 2006143153/04 A RU2006143153/04 A RU 2006143153/04A RU 2006143153 A RU2006143153 A RU 2006143153A RU 2386633 C2 RU2386633 C2 RU 2386633C2
- Authority
- RU
- Russia
- Prior art keywords
- compound
- diazabicyclo
- ylcarbonyl
- indazole
- hydroformate
- Prior art date
Links
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical class C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 title 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical class C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 title 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000004777 chromones Chemical class 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 118
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 16
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims abstract 10
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 201000010099 disease Diseases 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 5
- 239000001257 hydrogen Substances 0.000 claims abstract 5
- -1 tetrahydropyranyloxy Chemical group 0.000 claims abstract 5
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000004913 activation Effects 0.000 claims abstract 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 4
- 239000011737 fluorine Substances 0.000 claims abstract 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical group 0.000 claims abstract 4
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 2
- 230000002950 deficient Effects 0.000 claims abstract 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 8
- 206010012289 Dementia Diseases 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 5
- NNYZNICVOLLXNV-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-(6-methoxy-1,2-benzothiazol-3-yl)methanone Chemical compound N=1SC2=CC(OC)=CC=C2C=1C(=O)N1CCN2CCC1CC2 NNYZNICVOLLXNV-UHFFFAOYSA-N 0.000 claims 4
- PYWOMPMOIRJAPM-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(1,3-oxazol-2-yl)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=CC=2)=NNC1=CC=2C1=NC=CO1 PYWOMPMOIRJAPM-UHFFFAOYSA-N 0.000 claims 4
- YOSNUAVTCSGDDZ-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(3,6-dihydro-2h-pyran-4-yl)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=CC=2)=NNC1=CC=2C1=CCOCC1 YOSNUAVTCSGDDZ-UHFFFAOYSA-N 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 4
- 208000026139 Memory disease Diseases 0.000 claims 4
- AODOOQSKPNKDGP-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(1,3-thiazol-2-yl)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=C2)=NNC1=CC=C2C1=NC=CS1 AODOOQSKPNKDGP-UHFFFAOYSA-N 0.000 claims 3
- AVMFLZIPPMJCNT-UHFFFAOYSA-N 3-(1,4-diazabicyclo[3.2.2]nonan-4-ylmethyl)-5-methoxychromen-4-one Chemical compound O=C1C=2C(OC)=CC=CC=2OC=C1CN1CCN2CCC1CC2 AVMFLZIPPMJCNT-UHFFFAOYSA-N 0.000 claims 3
- UUTOCJOHQATTTQ-UHFFFAOYSA-N 3-(1,4-diazabicyclo[3.2.2]nonan-4-ylmethyl)-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC=C(C2=O)C=1OC=C2CN1CCN2CCC1CC2 UUTOCJOHQATTTQ-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 230000009225 memory damage Effects 0.000 claims 3
- 230000006984 memory degeneration Effects 0.000 claims 3
- 208000023060 memory loss Diseases 0.000 claims 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- QMOQIVAZETZFED-ACCUITESSA-N (3e)-3-(1,4-diazabicyclo[3.2.2]nonan-4-ylmethylidene)-5-methoxychromen-4-one Chemical compound O=C1C=2C(OC)=CC=CC=2OC\C1=C/N1CCN2CCC1CC2 QMOQIVAZETZFED-ACCUITESSA-N 0.000 claims 2
- QWLLJTBPGFFLMY-ACCUITESSA-N (3e)-3-(1,4-diazabicyclo[3.2.2]nonan-4-ylmethylidene)-6-methoxychromen-4-one Chemical compound O=C1C2=CC(OC)=CC=C2OC\C1=C/N1CCN2CCC1CC2 QWLLJTBPGFFLMY-ACCUITESSA-N 0.000 claims 2
- ZDXQIWPYXVYTHD-ACCUITESSA-N (3e)-3-(1,4-diazabicyclo[3.2.2]nonan-4-ylmethylidene)-7-methoxychromen-4-one Chemical compound C1OC2=CC(OC)=CC=C2C(=O)\C1=C\N1CCN2CCC1CC2 ZDXQIWPYXVYTHD-ACCUITESSA-N 0.000 claims 2
- DDAPYINAKKHJLC-UHFFFAOYSA-N (6-bromo-1,2-benzothiazol-3-yl)-(1,4-diazabicyclo[3.2.2]nonan-4-yl)methanone Chemical compound N=1SC2=CC(Br)=CC=C2C=1C(=O)N1CCN2CCC1CC2 DDAPYINAKKHJLC-UHFFFAOYSA-N 0.000 claims 2
- FGRJCFQXMBBUHZ-UHFFFAOYSA-N (6-cyclopropyl-1,2-benzothiazol-3-yl)-(1,4-diazabicyclo[3.2.2]nonan-4-yl)methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=CC=2)=NSC1=CC=2C1CC1 FGRJCFQXMBBUHZ-UHFFFAOYSA-N 0.000 claims 2
- YRXUTSNTOGXCAG-UHFFFAOYSA-N 1,2-benzothiazol-3-yl(1,4-diazabicyclo[3.2.2]nonan-4-yl)methanone Chemical compound N=1SC2=CC=CC=C2C=1C(=O)N1CCN2CCC1CC2 YRXUTSNTOGXCAG-UHFFFAOYSA-N 0.000 claims 2
- RPUVSGFFSWSZSP-UHFFFAOYSA-N 1,2-benzoxazol-3-yl(1,4-diazabicyclo[3.2.2]nonan-4-yl)methanone Chemical compound N=1OC2=CC=CC=C2C=1C(=O)N1CCN2CCC1CC2 RPUVSGFFSWSZSP-UHFFFAOYSA-N 0.000 claims 2
- BPQJXXAKRZXHNG-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl(1h-indazol-4-yl)methanone Chemical compound C=1C=CC=2NN=CC=2C=1C(=O)N1CCN2CCC1CC2 BPQJXXAKRZXHNG-UHFFFAOYSA-N 0.000 claims 2
- WFYGCMBOSHFWFP-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-(6-ethoxy-1,2-benzothiazol-3-yl)methanone Chemical compound N=1SC2=CC(OCC)=CC=C2C=1C(=O)N1CCN2CCC1CC2 WFYGCMBOSHFWFP-UHFFFAOYSA-N 0.000 claims 2
- KEKCXZWFFSZCOB-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-(7-methoxy-1,2-benzothiazol-3-yl)methanone Chemical compound N=1SC=2C(OC)=CC=CC=2C=1C(=O)N1CCN2CCC1CC2 KEKCXZWFFSZCOB-UHFFFAOYSA-N 0.000 claims 2
- LNNJOENXHAEGRO-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(1,3-oxazol-2-yl)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=C2)=NNC1=CC=C2C1=NC=CO1 LNNJOENXHAEGRO-UHFFFAOYSA-N 0.000 claims 2
- WCMSQISELPQCRY-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(3,6-dihydro-2h-pyran-4-yl)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=C2)=NNC1=CC=C2C1=CCOCC1 WCMSQISELPQCRY-UHFFFAOYSA-N 0.000 claims 2
- WNESJIBHOMFZCK-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(4-methyl-1,3-thiazol-2-yl)-1h-indazol-3-yl]methanone Chemical compound CC1=CSC(C=2C=C3C(C(=O)N4C5CCN(CC5)CC4)=NNC3=CC=2)=N1 WNESJIBHOMFZCK-UHFFFAOYSA-N 0.000 claims 2
- DTPPKDHXUUFAIV-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(5-methyl-1,3-thiazol-2-yl)-1h-indazol-3-yl]methanone Chemical compound S1C(C)=CN=C1C1=CC=C(NN=C2C(=O)N3C4CCN(CC4)CC3)C2=C1 DTPPKDHXUUFAIV-UHFFFAOYSA-N 0.000 claims 2
- SEBNFUUMYPXTBI-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(difluoromethoxy)-1h-indazol-3-yl]methanone Chemical compound C12=CC(OC(F)F)=CC=C2NN=C1C(=O)N1CCN2CCC1CC2 SEBNFUUMYPXTBI-UHFFFAOYSA-N 0.000 claims 2
- CSTWCHMJLKAATQ-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(oxan-4-yl)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=C2)=NNC1=CC=C2C1CCOCC1 CSTWCHMJLKAATQ-UHFFFAOYSA-N 0.000 claims 2
- RWCUXIYXZRHMQQ-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(oxan-4-yloxy)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=C2)=NNC1=CC=C2OC1CCOCC1 RWCUXIYXZRHMQQ-UHFFFAOYSA-N 0.000 claims 2
- CEBJANFQKVFHBE-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(1,3-thiazol-2-yl)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=CC=2)=NNC1=CC=2C1=NC=CS1 CEBJANFQKVFHBE-UHFFFAOYSA-N 0.000 claims 2
- KANQNVPNTJPKED-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(4-methyl-1,3-thiazol-2-yl)-1h-indazol-3-yl]methanone Chemical compound CC1=CSC(C=2C=C3NN=C(C3=CC=2)C(=O)N2C3CCN(CC3)CC2)=N1 KANQNVPNTJPKED-UHFFFAOYSA-N 0.000 claims 2
- LBDTVZWQTUGWFQ-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(5-methyl-1,3-thiazol-2-yl)-1h-indazol-3-yl]methanone Chemical compound S1C(C)=CN=C1C1=CC=C(C(=NN2)C(=O)N3C4CCN(CC4)CC3)C2=C1 LBDTVZWQTUGWFQ-UHFFFAOYSA-N 0.000 claims 2
- MTPZJIVGGBTVKG-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(difluoromethoxy)-1h-indazol-3-yl]methanone Chemical compound N=1NC2=CC(OC(F)F)=CC=C2C=1C(=O)N1CCN2CCC1CC2 MTPZJIVGGBTVKG-UHFFFAOYSA-N 0.000 claims 2
- ZKMAUIPCWKPPMA-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(oxan-4-yl)-1h-indazol-3-yl]methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=CC=2)=NNC1=CC=2C1CCOCC1 ZKMAUIPCWKPPMA-UHFFFAOYSA-N 0.000 claims 2
- COMJGIONTGURMB-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(trifluoromethoxy)-1,2-benzothiazol-3-yl]methanone Chemical compound N=1SC2=CC(OC(F)(F)F)=CC=C2C=1C(=O)N1CCN2CCC1CC2 COMJGIONTGURMB-UHFFFAOYSA-N 0.000 claims 2
- NWQFDFPTWNATRN-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(trifluoromethoxy)-1h-indazol-3-yl]methanone Chemical compound N=1NC2=CC(OC(F)(F)F)=CC=C2C=1C(=O)N1CCN2CCC1CC2 NWQFDFPTWNATRN-UHFFFAOYSA-N 0.000 claims 2
- VTXJUEMYYUZZNS-UHFFFAOYSA-N 1-[3-(1,4-diazabicyclo[3.2.2]nonane-4-carbonyl)-1,2-benzothiazol-6-yl]-3-methylimidazolidin-2-one Chemical compound O=C1N(C)CCN1C1=CC=C(C(=NS2)C(=O)N3C4CCN(CC4)CC3)C2=C1 VTXJUEMYYUZZNS-UHFFFAOYSA-N 0.000 claims 2
- CDESTGLMGICAED-UHFFFAOYSA-N 1-[3-(1,4-diazabicyclo[3.2.2]nonane-4-carbonyl)-1,2-benzothiazol-6-yl]-3-propan-2-ylimidazolidin-2-one Chemical compound O=C1N(C(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N3C4CCN(CC4)CC3)C2=C1 CDESTGLMGICAED-UHFFFAOYSA-N 0.000 claims 2
- BYUQALRPZHQOMF-UHFFFAOYSA-N 3-(1,4-diazabicyclo[3.2.2]nonan-4-ylmethyl)-6-methoxychromen-4-one Chemical compound O=C1C2=CC(OC)=CC=C2OC=C1CN1CCN2CCC1CC2 BYUQALRPZHQOMF-UHFFFAOYSA-N 0.000 claims 2
- ZHASMQOOVFRFCQ-UHFFFAOYSA-N 3-(1,4-diazabicyclo[3.2.2]nonane-4-carbonyl)chromen-4-one Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C(=O)N1CCN2CCC1CC2 ZHASMQOOVFRFCQ-UHFFFAOYSA-N 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- DRLIWCKHESTEFJ-UHFFFAOYSA-N [6-(cyclopropylmethoxy)-1,2-benzothiazol-3-yl]-(1,4-diazabicyclo[3.2.2]nonan-4-yl)methanone Chemical compound C1CN(CC2)CCC2N1C(=O)C(C1=CC=2)=NSC1=CC=2OCC1CC1 DRLIWCKHESTEFJ-UHFFFAOYSA-N 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- OVJSGHJLVRFCEB-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(1,3-thiazol-2-yl)-1h-indazol-3-yl]methanone;hydrochloride Chemical compound Cl.C1CN(CC2)CCC2N1C(=O)C(C1=C2)=NNC1=CC=C2C1=NC=CS1 OVJSGHJLVRFCEB-UHFFFAOYSA-N 0.000 claims 1
- SZTYPRKMELXJFS-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[5-(trifluoromethoxy)-1h-indazol-3-yl]methanone Chemical compound C12=CC(OC(F)(F)F)=CC=C2NN=C1C(=O)N1CCN2CCC1CC2 SZTYPRKMELXJFS-UHFFFAOYSA-N 0.000 claims 1
- VSNNWIAGFYGKRM-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(1,3-oxazol-2-yl)-1h-indazol-3-yl]methanone;hydrochloride Chemical compound Cl.C1CN(CC2)CCC2N1C(=O)C(C1=CC=2)=NNC1=CC=2C1=NC=CO1 VSNNWIAGFYGKRM-UHFFFAOYSA-N 0.000 claims 1
- UZKCXKGCVAZJRM-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-4-yl-[6-(3,6-dihydro-2h-pyran-4-yl)-1h-indazol-3-yl]methanone;hydrochloride Chemical compound Cl.C1CN(CC2)CCC2N1C(=O)C(C1=CC=2)=NNC1=CC=2C1=CCOCC1 UZKCXKGCVAZJRM-UHFFFAOYSA-N 0.000 claims 1
- JTPZTKBRUCILQD-UHFFFAOYSA-N 1-methylimidazolidin-2-one Chemical compound CN1CCNC1=O JTPZTKBRUCILQD-UHFFFAOYSA-N 0.000 claims 1
- RTPNQRLGWKMEEK-UHFFFAOYSA-N 1-propan-2-ylimidazolidin-2-one Chemical compound CC(C)N1CCNC1=O RTPNQRLGWKMEEK-UHFFFAOYSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000010340 Sleep Deprivation Diseases 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000001147 anti-toxic effect Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 230000003492 excitotoxic effect Effects 0.000 claims 1
- 231100000063 excitotoxicity Toxicity 0.000 claims 1
- 238000002695 general anesthesia Methods 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000035874 hyperreactivity Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000007087 memory ability Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 210000000225 synapse Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- YKBHIAMXELZBES-UHFFFAOYSA-N CN1C(CC2)CN2CC1 Chemical compound CN1C(CC2)CN2CC1 YKBHIAMXELZBES-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56869604P | 2004-05-07 | 2004-05-07 | |
| US60/568,696 | 2004-05-07 | ||
| US57471204P | 2004-05-27 | 2004-05-27 | |
| US60/574,712 | 2004-05-27 | ||
| US62646904P | 2004-11-10 | 2004-11-10 | |
| US60/626,469 | 2004-11-10 | ||
| PCT/US2005/015937 WO2005111038A2 (en) | 2004-05-07 | 2005-05-06 | 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006143153A RU2006143153A (ru) | 2008-06-20 |
| RU2386633C2 true RU2386633C2 (ru) | 2010-04-20 |
Family
ID=34969469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006143153/04A RU2386633C2 (ru) | 2004-05-07 | 2005-05-06 | 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7632831B2 (https=) |
| EP (1) | EP1745046B1 (https=) |
| JP (1) | JP2007538011A (https=) |
| KR (1) | KR20070015607A (https=) |
| AT (1) | ATE505470T1 (https=) |
| AU (1) | AU2005243147A1 (https=) |
| BR (1) | BRPI0510212A (https=) |
| CA (1) | CA2565984A1 (https=) |
| DE (1) | DE602005027452D1 (https=) |
| IL (1) | IL179033A0 (https=) |
| MX (1) | MXPA06012880A (https=) |
| NO (1) | NO20065622L (https=) |
| NZ (1) | NZ551712A (https=) |
| RU (1) | RU2386633C2 (https=) |
| WO (1) | WO2005111038A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456171B2 (en) * | 2002-10-08 | 2008-11-25 | Sanofi-Aventis | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof |
| US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2007135122A1 (en) * | 2006-05-23 | 2007-11-29 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use |
| JP5160764B2 (ja) * | 2006-10-13 | 2013-03-13 | 全薬工業株式会社 | 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 |
| NZ578096A (en) * | 2007-01-10 | 2011-11-25 | Albany Molecular Res Inc | 5-pyridinone substituted indazoles |
| CN101861311A (zh) * | 2007-07-21 | 2010-10-13 | 阿尔巴尼分子研究公司 | 5-吡啶酮取代的吲唑 |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| AU2008316895A1 (en) * | 2007-10-22 | 2009-04-30 | Memory Pharmaceuticals Corporation | (1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease |
| US8697722B2 (en) | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| ES2407647T3 (es) | 2008-10-13 | 2013-06-13 | F. Hoffmann-La Roche Ag | Método libre de diazonio para obtener un intermediario indazol en la síntesis de amidas de ácido bicíclico 5-(trifluorometoxi)-1H-3-indazol carboxílico |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| RU2560729C2 (ru) | 2010-01-11 | 2015-08-20 | АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи | Модуляторы никотиновых ацетилхолиновых рецепторов |
| US20110172428A1 (en) | 2010-01-12 | 2011-07-14 | Shan-Ming Kuang | Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt |
| MX2012013197A (es) | 2010-05-12 | 2013-04-03 | Abbvie Inc | Inhibidores de indazol de cinasa. |
| US8242276B2 (en) | 2010-06-30 | 2012-08-14 | Hoffmann-La Roche Inc. | Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| ES2712211T3 (es) | 2013-06-20 | 2019-05-09 | Bayer Cropscience Ag | Derivados de arilsulfuro y arilsulfóxido acaricidas e insecticidas |
| US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
| WO2018102885A1 (en) * | 2016-12-09 | 2018-06-14 | Bionomics Limited | Modulators of nicotinic acetylcholine receptors and uses thereof |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| JP7746384B2 (ja) * | 2020-12-08 | 2025-09-30 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１のベンゾピラゾール阻害剤 |
| WO2023101895A1 (en) * | 2021-11-30 | 2023-06-08 | Merck Sharp & Dohme Llc | Fused pyrazole urea analogs as glucosylceramide synthase inhibitors |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124014C1 (ru) * | 1993-12-29 | 1998-12-27 | Пфайзер Инк. | Диазабициклические соединения и содержащая их фармацевтическая композиция |
| WO2000058311A1 (fr) * | 1999-03-30 | 2000-10-05 | Sanofi-Synthelabo | Derives de 1,4-diazabicyclo[3.2.2]nonane-4-carboxylates et carboxamides, leur preparation et leur application en therapeutique |
| EP1219622A2 (en) * | 2000-12-29 | 2002-07-03 | Pfizer Products Inc. | Pharmaceutical compositions for CNS and other disorders |
| WO2003070728A2 (en) * | 2002-02-15 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders |
| US20030225268A1 (en) * | 1999-01-29 | 2003-12-04 | Bunnelle William H. | Diazabicyclic CNS active agents |
| WO2004016616A1 (en) * | 2002-08-14 | 2004-02-26 | Astrazeneca Ab | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists. |
| FR2845388A1 (fr) * | 2002-10-08 | 2004-04-09 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL59004A0 (en) | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
| FR2531083B1 (fr) | 1982-06-29 | 1986-11-28 | Sandoz Sa | Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments |
| JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
| FR2548666A1 (fr) | 1983-07-08 | 1985-01-11 | Delalande Sa | Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique |
| WO1985001048A1 (en) | 1983-08-26 | 1985-03-14 | Sandoz Ag | Aromatic esters or amides of carboxylic acid and sulfonic acid |
| US4605652A (en) | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
| DE3650772T2 (de) | 1985-04-27 | 2003-04-03 | F. Hoffmann-La Roche Ag, Basel | Derivate von Indazole-3-carboxamide und -3-carboxylsäure |
| US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
| GB8623142D0 (en) | 1986-09-26 | 1986-10-29 | Beecham Group Plc | Compounds |
| US5204356A (en) | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
| GB8518658D0 (en) | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Medicaments |
| GB8520616D0 (en) | 1985-08-16 | 1985-09-25 | Beecham Group Plc | Compounds |
| IN166416B (https=) | 1985-09-18 | 1990-05-05 | Pfizer | |
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| HU895334D0 (en) | 1986-07-30 | 1990-01-28 | Sandoz Ag | Process for the preparation of nasal pharmaceutical compositions |
| GB8701022D0 (en) | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| EP0340270B1 (en) | 1987-11-14 | 1992-07-15 | Beecham Group Plc | 5-ht 3? receptor antagonists for treatment of cough and bronchoconstriction |
| EP0350130A3 (en) | 1988-07-07 | 1991-07-10 | Duphar International Research B.V | New substituted 1,7-annelated 1h-indazoles |
| GB8823980D0 (en) * | 1988-10-13 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
| US4895943A (en) | 1988-10-25 | 1990-01-23 | Pfizer Inc. | Preparation of 1,4-diazabicyclo(3.2.2)nonane |
| US5223625A (en) | 1988-12-22 | 1993-06-29 | Duphar International Research B.V. | Annelated indolo [3,2,-C]lactams |
| EP0377238A1 (en) | 1988-12-22 | 1990-07-11 | Duphar International Research B.V | New annelated indolo (3,2-c)-lactams |
| WO1990014347A1 (fr) | 1989-05-24 | 1990-11-29 | Nippon Shinyaku Co., Ltd. | Derives d'indole et medicament |
| US5446050A (en) | 1989-11-17 | 1995-08-29 | Pfizer Inc. | Azabicyclo amides and esters as 5-HT3 receptor antagonists |
| GB8928837D0 (en) | 1989-12-21 | 1990-02-28 | Beecham Group Plc | Pharmaceuticals |
| US5098889A (en) | 1990-09-17 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
| US5192770A (en) | 1990-12-07 | 1993-03-09 | Syntex (U.S.A.) Inc. | Serotonergic alpha-oxoacetamides |
| HU211081B (en) | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| JPH06506443A (ja) | 1991-01-09 | 1994-07-21 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物 |
| AU1783492A (en) * | 1991-05-30 | 1993-01-08 | Tokyo Tanabe Company Limited | Quinoline derivative and production thereof |
| GB9121835D0 (en) | 1991-10-15 | 1991-11-27 | Smithkline Beecham Plc | Pharmaceuticals |
| US5273972A (en) | 1992-03-26 | 1993-12-28 | A. H. Robins Company, Incorporated | [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates |
| US5679673A (en) | 1992-09-24 | 1997-10-21 | The United States Of America, Represented By The Department Of Health And Human Services | Aralkyl bridged diazabicycloalkane derivatives for CNS disorders |
| IT1256623B (it) | 1992-12-04 | 1995-12-12 | Federico Arcamone | Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche |
| GB9406857D0 (en) | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6624173B1 (en) | 1997-06-30 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions for treating and/or preventing CNS disorders |
| US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
| FR2786770B1 (fr) * | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| SE9903760D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| JP2003534344A (ja) | 2000-05-25 | 2003-11-18 | ターガセプト，インコーポレイテッド | ニコチン性コリン受容体リガンドとしてのヘテロアリールジアザビシクロアルカン |
| FR2809732B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
| JP4616971B2 (ja) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | １−アザビシクロアルカン化合物およびその医薬用途 |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| AU2001282875A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6823207B1 (en) * | 2000-08-26 | 2004-11-23 | Ge Medical Systems Global Technology Company, Llc | Integrated fluoroscopic surgical navigation and imaging workstation with command protocol |
| WO2002036114A1 (en) | 2000-11-01 | 2002-05-10 | Respiratorius Ab | Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 |
| ATE348829T1 (de) | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| DE60203007T2 (de) | 2001-06-01 | 2005-07-07 | Neurosearch A/S | Heteroaryl-diazabicycloalkanderivaten als cns-modulatoren |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| WO2002100833A1 (en) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
| DE60218493D1 (de) | 2001-09-12 | 2007-04-12 | Pharmacia & Upjohn Co Llc | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten |
| CA2462453C (en) | 2001-10-02 | 2009-07-28 | Pharmacia & Upjohn Company | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| JP2005511574A (ja) | 2001-10-26 | 2005-04-28 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| MXPA04004373A (es) | 2001-11-09 | 2004-08-11 | Upjohn Co | Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades. |
| DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
| DE10162375A1 (de) | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
| DE10305922A1 (de) | 2002-06-10 | 2004-03-04 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CA2476624A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
| WO2003072578A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| DE10211415A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| ES2197001B1 (es) | 2002-03-26 | 2004-11-16 | Laboratorios Vita, S.A. | Procedimiento de obtencion de un compuesto farmaceuticamente activo. |
| CN100522976C (zh) | 2002-05-07 | 2009-08-05 | 神经研究公司 | 氮杂环乙炔基衍生物 |
| CN1656093A (zh) | 2002-05-30 | 2005-08-17 | 神经研究公司 | 3－取代的奎宁环及其用途 |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| WO2004014922A1 (en) | 2002-08-10 | 2004-02-19 | Astex Technology Limited | 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| US7456171B2 (en) | 2002-10-08 | 2008-11-25 | Sanofi-Aventis | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| DE602004023586D1 (de) | 2003-02-27 | 2009-11-26 | Neurosearch As | Neue diazabicyclische arylderivate |
| DE10334724A1 (de) | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| DE602004006767T2 (de) * | 2003-09-26 | 2008-02-07 | Astrazeneca Ab | Nichtamidnonane |
| FR2865208B1 (fr) * | 2004-01-16 | 2009-01-16 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique |
| BRPI0619672A2 (pt) * | 2005-11-09 | 2011-10-11 | Memory Pharm Corp | composto, composição farmacêutica, e, uso de um composto |
-
2005
- 2005-05-06 NZ NZ551712A patent/NZ551712A/en unknown
- 2005-05-06 CA CA002565984A patent/CA2565984A1/en not_active Abandoned
- 2005-05-06 EP EP05747486A patent/EP1745046B1/en not_active Expired - Lifetime
- 2005-05-06 RU RU2006143153/04A patent/RU2386633C2/ru not_active IP Right Cessation
- 2005-05-06 MX MXPA06012880A patent/MXPA06012880A/es active IP Right Grant
- 2005-05-06 KR KR1020067025685A patent/KR20070015607A/ko not_active Ceased
- 2005-05-06 DE DE602005027452T patent/DE602005027452D1/de not_active Expired - Lifetime
- 2005-05-06 US US11/123,219 patent/US7632831B2/en not_active Expired - Fee Related
- 2005-05-06 JP JP2007511654A patent/JP2007538011A/ja active Pending
- 2005-05-06 BR BRPI0510212-0A patent/BRPI0510212A/pt not_active IP Right Cessation
- 2005-05-06 AT AT05747486T patent/ATE505470T1/de active
- 2005-05-06 WO PCT/US2005/015937 patent/WO2005111038A2/en not_active Ceased
- 2005-05-06 AU AU2005243147A patent/AU2005243147A1/en not_active Abandoned
-
2006
- 2006-11-02 IL IL179033A patent/IL179033A0/en unknown
- 2006-12-06 NO NO20065622A patent/NO20065622L/no not_active Application Discontinuation
-
2009
- 2009-09-03 US US12/553,538 patent/US20090325939A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124014C1 (ru) * | 1993-12-29 | 1998-12-27 | Пфайзер Инк. | Диазабициклические соединения и содержащая их фармацевтическая композиция |
| US20030225268A1 (en) * | 1999-01-29 | 2003-12-04 | Bunnelle William H. | Diazabicyclic CNS active agents |
| WO2000058311A1 (fr) * | 1999-03-30 | 2000-10-05 | Sanofi-Synthelabo | Derives de 1,4-diazabicyclo[3.2.2]nonane-4-carboxylates et carboxamides, leur preparation et leur application en therapeutique |
| EP1219622A2 (en) * | 2000-12-29 | 2002-07-03 | Pfizer Products Inc. | Pharmaceutical compositions for CNS and other disorders |
| WO2003070728A2 (en) * | 2002-02-15 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders |
| US20030236279A1 (en) * | 2002-02-15 | 2003-12-25 | Walker Daniel Patrick | Substituted-aryl compounds for treatment of disease |
| WO2004016616A1 (en) * | 2002-08-14 | 2004-02-26 | Astrazeneca Ab | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists. |
| FR2845388A1 (fr) * | 2002-10-08 | 2004-04-09 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006143153A (ru) | 2008-06-20 |
| EP1745046A2 (en) | 2007-01-24 |
| MXPA06012880A (es) | 2007-01-26 |
| NZ551712A (en) | 2010-07-30 |
| NO20065622L (no) | 2007-02-02 |
| IL179033A0 (en) | 2007-03-08 |
| US20050272735A1 (en) | 2005-12-08 |
| US20090325939A1 (en) | 2009-12-31 |
| AU2005243147A1 (en) | 2005-11-24 |
| DE602005027452D1 (de) | 2011-05-26 |
| KR20070015607A (ko) | 2007-02-05 |
| US7632831B2 (en) | 2009-12-15 |
| WO2005111038A2 (en) | 2005-11-24 |
| EP1745046B1 (en) | 2011-04-13 |
| BRPI0510212A (pt) | 2007-10-16 |
| ATE505470T1 (de) | 2011-04-15 |
| WO2005111038A3 (en) | 2006-08-31 |
| JP2007538011A (ja) | 2007-12-27 |
| CA2565984A1 (en) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2386633C2 (ru) | 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения | |
| RU2417225C2 (ru) | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение | |
| RU2450003C2 (ru) | Индазолы, бензотиазолы, бензоизотиазолы, бензоизоксазолы, пиразолопиридины, изотиазолопиридины, их получение и их применение | |
| JP2007538011A5 (https=) | ||
| RU2391341C2 (ru) | Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение | |
| RU2006126540A (ru) | Индолы, 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение | |
| US8637510B2 (en) | Morpholinothiazoles as alpha 7 positive allosteric modulators | |
| JP2008525464A5 (https=) | ||
| JP2005516006A5 (https=) | ||
| RU2007128062A (ru) | Лиганды никотинового рецептора а-7, их получение и применение | |
| JP2019523233A5 (https=) | ||
| RU2004121166A (ru) | 2-аминобензотиазолилмочевины в качестве модуляторов аденозина | |
| JP2018530591A5 (https=) | ||
| JP2005510473A5 (https=) | ||
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| RU2015120217A (ru) | Замещенные 1,6-нафтиридины | |
| JP2019537592A5 (https=) | ||
| RU2006124559A (ru) | Производные нафтиридина и применение указанных производныхых в качестве модуляторов мускариновых рецепторов | |
| JP2003513071A5 (https=) | ||
| RU2006125636A (ru) | Лиганды никотиновых рецепторов ацетилхолина | |
| JP2007515479A5 (https=) | ||
| KR20230035349A (ko) | 수면 무호흡의 치료를 위한 알파2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 task1/3 채널 차단제의 조합물 | |
| JP2022548859A5 (https=) | ||
| JP2007063277A (ja) | Ｃｎｓの病気を治療するための５−ｈｔ１ｂアンタゴニスト組成物 | |
| ZA200608812B (en) | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120507 |